Westbourne Investments Inc. Takes $2.41 Million Position in Pfizer Inc. $PFE

Key Points

• Westbourne Investments Inc. acquired 95,165 shares of Pfizer Inc. valued at approximately $2.4 million, making it the firm’s 15th largest holding.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, exceeding estimates by $0.20, with revenues of $14.65 billion, a 10.3% increase year-over-year.
• Pfizer's consensus rating is "Hold," with price targets ranging from $25.00 to $33.00 given by various financial institutions.

Westbourne Investments Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 95,165 shares of the biopharmaceutical company's stock, valued at approximately $2,411,000. Pfizer comprises about 1.5% of Westbourne Investments Inc.'s investment portfolio, making the stock its 15th biggest holding.

Several other hedge funds have also recently bought and sold shares of PFE. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth $27,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth $28,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter valued at $30,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 1.1%

PFE stock traded up $0.27 during mid-day trading on Thursday, hitting $24.84. The stock had a trading volume of 36,770,116 shares, compared to its average volume of 34,782,688. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a fifty day moving average of $24.82 and a 200 day moving average of $24.32. The stock has a market capitalization of $141.23 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several analysts have recently weighed in on PFE shares. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.